← All trials
NCT04943627
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2021
- Primary completion
- Oct 22, 2021
- Completion date
- Oct 22, 2021
- First posted
- Jun 29, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Agenus Inc.Lead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Agenus Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.